Welcome to our dedicated page for Mediwound SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MediWound Ltd. (MDWD) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. MediWound files reports on Form 6-K to furnish press releases, financial statements, and transaction details, and uses shelf registration statements on Form F-3 and employee share plans on Form S-8 for capital markets activities. These documents provide structured insight into the company’s biotechnology business focused on enzymatic, non-surgical therapies for tissue repair.
In its Form 6-K filings, MediWound furnishes quarterly and interim financial results, including condensed consolidated statements of financial position and profit or loss, along with management press releases discussing revenue, operating loss, cash balances, and non-IFRS measures such as Adjusted EBITDA. Other 6-Ks describe registered direct offerings of ordinary shares under an effective Form F-3 shelf registration statement, including purchase agreements, use of proceeds for EscharEx® pre-commercial activities and manufacturing expansion, and related legal opinions.
Filings also reference government-supported programs and contracts that are important to MediWound’s burn and chronic wound portfolio. BARDA- and U.S. Department of Defense-funded projects for NexoBrid®, including clinical development, regulatory submissions, emergency procurement, and formulation work, are discussed in the company’s press releases that are incorporated by reference into SEC reports. Insider share purchases by senior leadership are reported on Form 6-K, providing transparency into management’s trading activity.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain key points from lengthy filings, highlight changes in financial condition, and surface important details about offerings, grants, and clinical or manufacturing milestones. Users can quickly locate quarterly updates, registration statements, and reports that reference NexoBrid and EscharEx, and review how MediWound describes its risks, funding, and strategic priorities over time.
MediWound Ltd. executive Hess Shmuel, the company’s COO and Chief Commercial Officer, reported his existing equity stake in a Form 3 insider filing. The filing lists stock options to acquire 32,000, 32,681, 24,000 and 31,000 ordinary shares at exercise prices of $8.1292, $12.7290, $18.5400 and $17.6000, expiring between December 1, 2033 and March 4, 2036.
He also reports direct holdings of 4,085, 3,000 and 3,800 ordinary shares, which footnotes explain are tied to restricted share units granted in 2024, 2025 and 2026, each vesting over four years. The Form 3 establishes his current ownership position and does not show any recent share purchases or sales.
MediWound Ltd. Chief Executive Officer Gonen Ofer filed an initial ownership report detailing his equity and derivative holdings in the company. The filing lists direct holdings of ordinary shares and multiple grants of restricted share units (RSUs) and stock options that vest over four-year schedules.
The report shows Series A Warrants exercisable into 8,168 ordinary shares at an exercise price of 13.4750 per share, expiring on November 28, 2026. It also outlines several stock option grants over different years, with exercise prices ranging from 11.8850 to 18.5400 per share and expirations from 2032 through 2036. Footnotes explain that both RSUs and options vest 25% after one year from grant and 6.25% each quarter over the next three years, providing long-term, performance-linked compensation rather than immediate open-market transactions.
MediWound Ltd. director Nachum Shamir has filed a Form 3 showing his initial ownership in the company. He directly holds 49,815 ordinary shares and an additional 1,200 ordinary shares underlying restricted stock units granted on March 4, 2026, which vest in full one year after the grant date.
He also holds a series of equity derivatives over MediWound ordinary shares. These include Series A warrants over 16,336 shares at an exercise price of 13.4750 per share expiring on November 28, 2026, and several stock option grants covering 28,571, 11,800, 12,570, 9,200 and 10,000 underlying shares with exercise prices between 11.8850 and 18.5400, expiring between August 17, 2032 and March 4, 2036. The options granted on March 4, 2026 vest 100% on the one-year anniversary of the grant date.
MediWound Ltd. files its 2025 annual report on Form 20-F, detailing its burn- and wound-care business, risk profile and financial position. The company reports a net loss of $23.9 million for 2025 and an accumulated deficit of $228.9 million as of year-end.
As of December 31, 2025, MediWound had 12,835,148 ordinary shares outstanding. The filing highlights reliance on NexoBrid sales, partner Vericel in North America, government contracts for temperature-stable NexoBrid, and a new GMP facility in Yavne, Israel that reached full manufacturing capacity in 2025.
MediWound Ltd. files its 2025 annual report on Form 20-F, detailing its burn- and wound-care business, risk profile and financial position. The company reports a net loss of $23.9 million for 2025 and an accumulated deficit of $228.9 million as of year-end.
As of December 31, 2025, MediWound had 12,835,148 ordinary shares outstanding. The filing highlights reliance on NexoBrid sales, partner Vericel in North America, government contracts for temperature-stable NexoBrid, and a new GMP facility in Yavne, Israel that reached full manufacturing capacity in 2025.
MediWound Ltd. reported 2025 revenue of $16.96M, down from $20.22M in 2024, while net loss narrowed to $23.88M from $30.22M. Gross profit improved modestly, but Adjusted EBITDA loss widened to $20.31M from $14.76M, reflecting higher operating spending.
For the fourth quarter, revenue fell to $1.87M from $5.84M, with net loss deepening to $7.18M. Cash and short-term bank deposits were $53.14M as of December 31, 2025, and shareholders’ equity increased to $43.63M.
The company highlighted two key growth drivers: its Phase III EscharEx VALUE trial, expected to reach interim assessment and enrollment completion by year-end, and an expanded, operational NexoBrid manufacturing facility, with regulatory approvals expected in 2026. Management reaffirmed 2026–2028 revenue guidance.
MediWound Ltd. reported 2025 revenue of $16.96M, down from $20.22M in 2024, while net loss narrowed to $23.88M from $30.22M. Gross profit improved modestly, but Adjusted EBITDA loss widened to $20.31M from $14.76M, reflecting higher operating spending.
For the fourth quarter, revenue fell to $1.87M from $5.84M, with net loss deepening to $7.18M. Cash and short-term bank deposits were $53.14M as of December 31, 2025, and shareholders’ equity increased to $43.63M.
The company highlighted two key growth drivers: its Phase III EscharEx VALUE trial, expected to reach interim assessment and enrollment completion by year-end, and an expanded, operational NexoBrid manufacturing facility, with regulatory approvals expected in 2026. Management reaffirmed 2026–2028 revenue guidance.
MediWound Ltd. reported the results of an extraordinary general meeting of shareholders. As of the January 16, 2026 record date, there were 12,815,094 ordinary shares outstanding and entitled to vote. Shareholders holding 3,844,528 ordinary shares, about 30% of the outstanding shares, were present in person or by proxy, satisfying the quorum requirements under the company’s Articles of Association and Israeli Companies Law.
The single proposal presented at the meeting was approved by the requisite majority under the Israeli Companies Law, excluding abstentions. The final vote count showed 3,490,863 votes in favor (90.9%), 350,902 votes against (9.1%), and 2,763 abstentions. The 6-K and its exhibits are incorporated by reference into MediWound’s existing Form S-8 and Form F-3 registration statements.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G/A reporting its beneficial ownership of 554,498 shares of MediWound Ltd. common stock, representing 4.3% of the class as of the event date. The firm has sole voting power over 535,181 shares and sole dispositive power over 554,498 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MediWound. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.
HOLD Alapkezelo Zrt., a Hungarian investment fund management company, filed an amended ownership report showing a significant stake in MediWound Ltd. common shares.
The firm is deemed to beneficially own 1,039,954 common shares, representing approximately 8.1% of MediWound’s outstanding common stock, based on 12,835,186 shares outstanding as of January 16, 2026. HOLD Alapkezelo Zrt. has sole voting and sole dispositive power over all of these shares and no shared voting or dispositive power.
The filer certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of MediWound, and are not held in connection with any control-related transaction.
MediWound Ltd. reported ownership by a Rosalind-affiliated group in a Schedule 13G/A. Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon together report beneficial ownership of 912,319 MediWound common shares, or 7% of the class, based on 12,835,186 shares outstanding as of January 16, 2026.
The filing explains that this figure includes 163,265 shares issuable upon exercise of warrants that are subject to a 9.99% ownership blocker. Excluding those blocked warrants, Rosalind Master Fund may be deemed to beneficially own 749,054 shares, or about 5.84% of the common stock. The group states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of MediWound.
MediWound Ltd. investor Yelin Lapidot group reports a 5.95% passive stake in the company’s ordinary shares. Amendment No. 1 to Schedule 13G shows Yelin Lapidot Holdings Management Ltd., together with Dov Yelin and Yair Lapidot, beneficially owning 763,069 ordinary shares with shared voting and dispositive power.
The stake is held through mutual and provident funds managed by wholly owned subsidiaries of Yelin Lapidot Holdings, for the benefit of fund members. The reporting persons expressly state the securities were not acquired and are not held to change or influence control of MediWound.